AJANTPHARM.BOAJANTPHARM.BOBSE
Loading
Year-over-year research & development expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P44
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
1.01%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 12.50% |
| Q2 2025 | -11.11% |
| Q1 2025 | 18.87% |
| Q4 2024 | -7.02% |
| Q3 2024 | 11.76% |
| Q2 2024 | 2.00% |
| Q1 2024 | -3.85% |
| Q4 2023 | 4.00% |
| Q3 2023 | -9.09% |
| Q2 2023 | -12.70% |
| Q1 2023 | 3.28% |
| Q4 2022 | 3.39% |
| Q3 2022 | 9.26% |
| Q2 2022 | -9.00% |
| Q1 2022 | 16.35% |
| Q4 2021 | 4.08% |
| Q3 2021 | 8.89% |
| Q2 2021 | 15.65% |
| Q1 2021 | -2.73% |
| Q4 2020 | 37.93% |
| Q3 2020 | -6.45% |
| Q2 2020 | -38.21% |
| Q1 2020 | 43.34% |
| Q4 2019 | -12.50% |
| Q3 2019 | 0.00% |
| Q2 2019 | -0.05% |
| Q1 2019 | -11.07% |
| Q4 2018 | -10.00% |
| Q3 2018 | 21.95% |
| Q2 2018 | -15.01% |
| Q1 2018 | 12.19% |
| Q4 2017 | -10.42% |
| Q3 2017 | 2.13% |
| Q2 2017 | 29.37% |
| Q1 2017 | -19.27% |
| Q4 2016 | 21.62% |
| Q3 2016 | 0.00% |
| Q2 2016 | -100.00% |
| Q1 2016 | 40.27% |